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ABSTRACT
This study calculated the net benefit of using active management of the third stage of labour (AMTSL) 
rather than expectant management of the third stage of labour (EMTSL) for mothers in Guatemala and 
Zambia. Probabilities of events were derived from opinions of experts, publicly available data, and 
published literature. Costs of clinical events were calculated based on national price lists, observation 
of resources used in AMTSL and EMTSL, and expert estimates of resources used in managing postpar-
tum haemorrhage and its complications, including transfusion. A decision tree was used for modelling 
expected costs associated with AMTSL or EMTSL. The base case analysis suggested a positive net 
benefit from AMTSL, with a net cost-saving of US$ 18,000 in Guatemala (with 100 lives saved) and 
US$ 145,000 in Zambia (with 467 lives saved) for 100,000 births. Facilities have strong economic 
incentives to adopt AMTSL if uterotonics are available.
Key words: Postpartum haemorrhage; Labour stage, Third; Cost and cost analysis; Cost-benefit analy-
sis; Guatemala; Zambia
INTRODUCTION
Active management of the third stage of labour (AMT-
SL) refers to a sequence of clinical actions taken by the 
skilled birth attendant to facilitate the delivery of the 
placenta, by promoting uterine contraction and placen-
tal expulsion. AMTSL, an alternative to physiological, 
or expectant management of the third stage of labour 
(EMTSL), reduces the incidence of postpartum haemor-
rhage which is the leading cause of maternal mortality 
worldwide (1,2). 
  Non-governmental organizations (NGOs) have 
been working with ministries of Health and Education 
in Guatemala and Zambia for several years on strate-
gies to improve maternal and child health. The U.S. 
Agency for International Development (USAID)-fund-
ed Maternal and Neonatal Health Global Programme, 
implemented by the JHPIEGO Corporation, USA, se-
lected AMTSL as a priority intervention in these two 
countries. The maternal mortality ratio (MMR) report-
ed in the most recent demographic and health survey 
(DHS) conducted in Guatemala in 1999 (3) is 190 per 
100,000 livebirths, or 240 when adjusted for method 
of computation (4), and 153 per 100,000 livebirths in a 
recent reproductive age mortality study (5). In Zambia, 
the MMR is 729 per 100,000 livebirths (750 adjusted) 
(6). 
  The promotion of AMTSL has occurred through 
policy advocacy, pre-service, and continuing education 
of healthcare providers. Experience has demonstrated 
that skilled birth attendants can be readily taught the 
techniques of AMTSL. However, to date, no cost-bene-
fit or cost-effectiveness analysis has been conducted 
to indicate whether the additional costs of personnel 
and material resources relating to the use of AMTSL 
would be offset by costs avoided by achieving better 
maternal outcomes. Averted costs result from avoid-
ing postpartum haemorrhage and, in turn, conserving 
resources required for the management of postpartum 
haemorrhage. An analysis was undertaken to fill this 
information gap and to demonstrate the utility of the 
intervention in two countries that varied greatly in their 
geographic and demographic context. Evidence of the 
potential cost-savings of routine AMTSL for health fa-
cilities could help foster the wide adoption of this life-
saving technique.MATERIALS AND METHODS
Definition of study variables
A set of three clinical interventions distinguishes AMT-
SL from expectant management. EMTSL, also known 
as conservative or physiological management, involves 
waiting for signs of separation of the placenta and al-
lowing the placenta to deliver spontaneously. The ear-
ly definition of AMTSL included: (a) intramuscular 
administration of a prophylactic uterotonic after the de-
livery of the baby; (b) early cord-clamping and cutting; 
and (c) controlled traction on the umbilical cord (7-9). 
Oxytocin was the synthetic agent used in the earliest 
clinical trials (10,11). Other uterotonics (ergometrine, 
syntometrine, and misoprostol) (12-17) and alternative 
routes of administration have recently been explored 
(18-20). The practice of early cord-clamping and cut-
ting has recently been de-emphasized (21), and uterine/
fundal massage is now recommended to ensure con-
traction of the uterus after the delivery of the placenta. 
These components have been delineated in the recent 
policy statement of the International Confederation of 
Midwives and the International Federation of Gyne-
cology and Obstetrics which recommends the practice 
of AMTSL (22). These three components are clinical 
events that can be objectively observed and verified.
  Postpartum haemorrhage was defined for the pur-
pose of this study as loss of blood after childbirth in 
excess of 500 mL (23). The definition of postpartum 
haemorrhage was further restricted to haemorrhage 
from uterine atony, including atony secondary to re-
tained placenta, which is the most prominent leading 
cause (with estimates of 80% or greater) of this com-
plication (2). Haemorrhage from cervical or vaginal 
lacerations was not addressed as this is not affected by 
AMTSL. Clinical estimates of postpartum haemor-
rhage typically depend on the judgment of the practition-
er with no attempt to verify actual loss of blood through 
approaches, such as collecting and measuring fluids 
(24). Visual estimation of blood loss is recognized as 
inaccurate, especially at the higher limits of measured 
blood loss (25). Nevertheless, this is the standard and 
pragmatic approach which is typically combined with 
a clinical judgment about the health status of women 
(26,27) in making a final assessment about further 
treatment. Treatment as determined by the provider ul-
timately leads to costs that AMTSL is expected to mini-
mize.
Estimating probabilities
Reliable estimates of country-specific probabilities for 
certain study-relevant variables were not readily acces-
sible. Both facility-based statistics and national vital 
registration records are considered incomplete in both 
the study countries. Therefore, probability estimates 
used for calculations of the net benefit of AMTSL came 
from several sources, including published literature, 
informed clinicians, and the consensus opinion of ex-
pert panels. JHPIEGO staff selected the panel mem-
bers based on their current academic, administrative 
or clinical affiliations as likely to be cognizant of con-
temporary epidemiologic or obstetrical clinical practice 
issues and patterns. The panel members selected the 
probabilities of specific events that, in their judgment, 
best reflected the actual situation in their country.
  Estimates of medical probabilities that were required 
to answer the study question included the likelihood of 
occurrence of postpartum haemorrhage with EMTSL, 
postpartum haemorrhage with AMTSL, and mortality, 
and the probability of each of the expected combina-
tions of clinical management strategies of postpartum 
haemorrhage. These strategies included: (a) uterotonic 
(UT) only; (b) uterotonic plus manual removal of the 
placenta (MRP); (c) uterotonic plus bimanual compres-
sion of the uterus (BMC); (d) uterotonic plus MRP and 
bimanual compression. The probability of transfusion 
in combination with any of the management strategies 
was also estimated. 
  Rates of maternal mortality and postpartum haemor-
rhage were obtained from publicly-available resources 
(3,6,28,29). The incidence of postpartum haemor-
rhage in three randomized clinical trials that compared 
AMTSL with EMTSL ranged from 5.8% to 6.8% (ac-
tive) and from 11% to 17.9% (physiologic) when post-
partum haemorrhage was defined as loss of 500 mL 
blood with lower incidence when the volume of blood 
loss was set at higher level (2,7-9). We used a 5% rate 
of postpartum haemorrhage with AMTSL and a 10% 
rate with EMTSL in this study. These figures were 
selected based on the recommendation of the expert 
panels. Country-specific estimates were acknowledged 
by panel members to be lower-bound, conservative es-
timates of the actual rates in each country, based on in-
complete statistical data, and are, therefore, neither 
precise nor reliable. If cost-savings could be demon-
strated using these lower-bound estimates, cost-savings 
would be even more certain if the true differences in 
the rates of postpartum haemorrhage with and without 
AMSTL were within the higher ranges cited above. 
  The panel members provided probability estimates 
for various combinations of management strategies of 
postpartum haemorrhage as practised in their respec-
tive countries. As clinical management strategies for 
the control of haemorrhage depend, at least in part, on 
the skill of practitioner and resources at hand (30,31), 
AMTSL cost-savings 541the choice of management strategies varies. However, 
the primary and most often effective clinical interven-
tion is the use of an uterotonic agent. Oxytocin is most 
commonly used. Experts indicated the relative use of 
oxytocin and alternative uterotonic agents. Secondary 
lifesaving interventions to manage postpartum haemor-
rhage include MRP and bimanual compression of the 
uterus (32). MRP and bimanual compression can be 
used individually or together and are virtually al-
ways combined with the use of a uterotonic. Although 
other medical and surgical interventions are available 
(33-37), their use was so rare in Guatemala and Zam-
bia that they were excluded from the analysis. Experts 
were also asked about the probability of transfusion.
Estimating costs
Recurrent costs addressed in these analyses included 
supplies, resources, and personnel used for providing 
AMTSL and EMTSL and for managing postpartum 
haemorrhage. In general, cost estimates were readily 
available and came from national cost lists and pur-
chasing officers. Estimates of the amounts of supplies 
used came from two sources. Research personnel ob-
served the third stage of labour in both the countries to 
determine the supplies used for AMTSL and EMTSL. 
Experts provided estimates of supplies used during the 
clinical management of postpartum haemorrhage.
  The facility perspective on costs was used in the 
analysis. The facility’s unit costs for materials were 
determined from purchasing officers and standard 
country-specific price lists. Patients had to buy their 
own supplies, or the supplies were donated rather than 
purchased by the facilities in some cases in both the 
countries. Every attempt was made to document these 
practices so that estimates of actual facility costs could 
be made.
  The compensation for services of doctors and 
nurses and facility costs relating to care of patients 
were more difficult to document. These were estimated 
based on the usual staffing patterns, average rates of 
compensation for several categories of care-givers, ave-
rage length of stay of the patient for uncomplicated 
labour and delivery and/or the need for transfusion.
  Costs of supplies and personnel for the surgical 
management of postpartum haemorrhage or its com-
plications were not estimated. Based on available use 
statistics and on the expressed opinions of informed ex-
perts, it was determined that these surgical modalities 
were very rarely employed.
  All prices were translated into US dollars using 
the prevailing bank rates (August 2004). Information 
obtained from the expert panel and from literature on 
probabilities of events and probabilities of clinical 
management strategies and information on the average 
number of supplies used in directly-observed clinical 
events (described below) was combined with the aver-
age cost per unit of supplies obtained from purchasing 
officers and price lists. The result was the average cost 
per clinical event.
  The approaches used for deriving country-specific 
estimates of the study variables are summarized in Ta-
ble 1. The probabilities used in the study are presented 
in Table 2. Certain assumptions were made as the basis 
for several analytical calculations. These assumptions 
are documented in the context of discussion of rele-
vant findings.
Study design 
A two-group study designed to measure the costs as-
sociated with AMTSL and EMTSL was implemented 
concurrently in the two study countries. Hospital fa-
cilities in both urban and rural settings were selected to 
reduce any bias that might be introduced by the relative 
advantages of urban settings. These facilities were also 
selected to represent various levels of emergency obs-
tetric care capacity available in the country.
  AMTSL has already been demonstrated to be of 
benefit, and the practice has been recommended for 
adoption in both the countries (22). Therefore, neither 
practitioners nor pregnant women were randomized 
to an intervention group. Instead, actual clinical prac-
tices were observed and described. Women were asked 
for their consent for observation and documentation 
of the events of their labour, delivery, and postpartum 
experiences. Verbal consent for this observation was 
documented on study forms. No personal identifying 
information was recorded on any study form. Provid-
ers (doctor, midwife, nurse, auxiliary nurse) were as-
sured that the choices that they made during clinical 
management were not the subject of this study and that 
the quality of their practice was not under review. The 
ministries of health in both the countries approved the 
design and implementation of the study in their respec-
tive jurisdiction. 
  Direct observation of births by the study consultants 
and research assistants allowed for the documentation 
of types, quantities, and costs of supplies used from the 
time of birth through a 30-minute observation period 
following the delivery of the placenta. Management 
strategies of postpartum haemorrhage or interventions 
that occurred following this 30-minute observation pe-
riod were not directly observed, but, rather, were es-
timated in the analysis based on the probabilities of 
occurrence developed for the study. In Guatemala, 30 
actively-managed and 30 expectantly-managed cases 
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Type of data Data source Method
Probability of events
Estimates of probabilities of major
  perinatal outcomes (PPH, 
  maternal mortality)
Published literature
Verified by expert panel
Internet and library resources
Group interview
Estimates of probabilities of use of 
  various options for clinical 






Internet and library resources
Costs of events
Type and amount of supplies used 
  in AMTSL Practising clinicians Direct observation
Type and amount of supplies used 
  in EMTSL Practising clinicians Direct observation
Type and amount of supplies used
  in clinical management of PPH Expert panel Group interview
Cost of supplies (personnel and 
  materials)
Informed sources (Personnel 
in charge of various units, e.g. 
Human Resources, Laboratory, 
Purchasing, Blood Bank)
Personal interview
Published cost lists (e.g. purchase 
orders, pharmacy price lists)
*Members of the expert panel in Zambia: 2 obstetrician/gynecologists, 3 midwives, 1 physician (other specialty), 
1 administrator of a birthing facility, and 1 pharmacy representative 
Members of the expert panel in Guatemala: 2 MCH training coordinators, 2 representatives from Ministry of 
Health, and 5 obstetrician/gynecologists
AMTSL=Active management of the third stage of labour; EMTSL=Expectant management of the third stage of 
labour; PPH=Postpartum haemorrhage
Table 2. Probabilities of events
Management and complications of PPH Guatemala Zambia
Postpartum haemorrhage
   With AMTSL 0.05 0.05
   With EMTSL 0.10 0.10
PPH management strategies
   UT only 0.81 0.39
   UT and MRP 0.12 0.22
   UT, MRP, and BMC 0.07 0.25
   UT and BMC 0.00 0.14
All management strategies 1.00 1.00
Complications (independent probabilities)
   Transfusion 0.10 0.46
   Death 0.02 0.09
AMTSL=Active management of the third stage of labour; BMC=Bimanual compression;
EMTSL=Expectant management of the third stage of labour; MRP=Manual removal of the placenta; 
PPH=Postpartum haemorrhage; UT=Uterotonic
were observed in four sites during May 2004. In Zam-
bia, 23 actively-managed and 15 expectantly-managed 
cases were observed across six sites from February to 
April 2004.
The study sites in Guatemala included government hos-
pitals that were each capable of providing emergency 
obstetric care (EOC). The hospitals were located at dis-
tances of 28-218 km from the capital Guatemala City. 
AMTSL cost-savings 543The number of births per facility ranged from 200 to 
500 a month. Clinical providers of care included physi-
cians, nurses, and auxiliary nurses.
  The study sites in Zambia included the University 
Teaching Hospital located in the capital city (Lusaka), 
three district health centres in the Lusaka community, 
and two hospitals and one health centre located 150-
350 km away from Lusaka. The number of births per 
facility ranged from 28 to 750 a month. Physicians 
and registered or enrolled midwives were the clinical 
providers of care. Each of the hospitals was capable of 
providing EOC. Patients of the health centres would 
be referred to these same hospitals, if in need of EOC 
services.
Study instruments
A supply checklist was developed and revised through 
reviews by international medical experts, several in-
country clinical observations, and interviews with key-
informants in both the countries. The final checklist 
reflected the usual and customary practices in the coun-
try sites. It also reflected the availability of material re-
sources and, therefore, it contained items commonly 
used as substitutes for items that were out-of-stock or 
otherwise not available. The country-specific supply 
checklists differed only by inclusion or exclusion of 
certain supplies as appropriate for the country.
Data analysis
Cost-benefit analysis
Cost-benefit analysis was made to compare the extra 
costs of administering AMTSL to a hypothetical popu-
lation of 100,000 births with expected cost-savings that 
result from fewer cases of postpartum haemorrhage 
and associated complications. Figure 1 reflects that the 
incidence of postpartum haemorrhage depends on the 
type of management of the third stage of labour. Fig-
ure 2 shows the events that occurred after postpartum 
haemorrhage which contributed to the calculation of 
the average cost per case of postpartum haemorrhage. 
The analytical approach used in this analysis assumed 
the independence of clinical events in the management 
of postpartum haemorrhage. Providers may choose one 
or more in various combinations. The choices for clini-
cal management of complications are not influenced by 
the third stage management approach that was used.
  The ‘base case’ analysis used the parameters de-
rived from the literature, expert panel, and observation. 
(The actual calculations for Guatemala are provided in 
the Appendix). All savings occur because of decreased 
risk of postpartum haemorrhage. The costs of postpar-
tum maternal care will be lower for the AMTSL group 
because there are fewer cases of postpartum haemor-
rhage. The net costs of AMTSL will be negative (i.e. it 
will be cost-saving) if the savings are sufficiently large 
to offset the costs of providing AMTSL to the popu-
lation. The results may vary between Guatemala and 
Zambia because of different prices, different probabili-
ties of clinical management strategies of postpartum 
haemorrhage, and different probabilities of transfusion 
and death (38). While we did not assign a cost of death 
from the facility perspective, the decreased number of 
deaths is useful information for policy-makers.
Sensitivity analyses
Three additional sets of analyses were performed to 
assess the robustness of findings using base case para-
meters. In the first and primary sensitivity analysis, we 
varied the probability of different clinical management 
strategies of postpartum haemorrhage. All 286 combi-
nations of probabilities of four strategies adding up to 
100%, with each being a multiple of 10%, were used in 
sensitivity analysis. This variation was allowed to ac-
count for the fact that a slightly different, but poten-
tially confounding, question was asked of respondents 
in the two countries. Results robust to this set of analy-
ses would indicate that assumptions made about man-
agement strategies of postpartum haemorrhage are not 
driving the result as long as postpartum haemorrhage is 
managed the same after either AMTSL or EMTSL. In a 
second sensitivity analysis for Zambia, results were re-
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i.e. the mean across the two countries (39).
  We kept the cost calculations completely separate 
in the two countries, recognizing that, between Zam-
bia and Guatemala, the available resources, the medi-
cal practices, and both absolute and relative costs are 
different. Other cost studies reported for multinational 
clinical trials have combined subjects and used an ave-
rage cost basis; however, in these cases, participating 
countries were much more similar on these parame-
ters.
  Finally, threshold analyses were conducted for 
each country. These calculations generated information 
about the minimum number of percentage points that 
the probability of postpartum haemorrhage would need 
to decrease  to achieve a positive net benefit from the 
introduction of AMSTL as a clinical policy and prac-
tice.
RESULTS
Table 3 depicts the base case results for both the coun-
tries under theoretical conditions where AMSTL is or 
is not used. The results for Guatemala demonstrate a 
net cost-saving of US$ 18,000 and 100 maternal deaths 
averted if AMTSL were used in 100,000 births. The re-
sults for Zambia demonstrate a net cost-saving of over 
US$ 145,000 and 467 maternal deaths averted when 
AMTSL is practised in 100,000 births. Both the sets 
of results indicate that AMTSL is cost-saving at the fa-
cility level.
  The results in Guatemala were robust. The non-
negative net benefit did not depend on the proportion 
of postpartum haemorrhage cases managed with each 
modality. Holding the probability of postpartum haemor-
rhage fixed at 10% with expectant management, the 
threshold analysis indicated that probability of postpar-
tum haemorrhage could be no higher than 6.2% (nearly 
80% of the base case effect) with AMTSL to yield cost-
savings for the facility.
  The findings in Zambia are similarly robust. Again, 
the non-negative results were invariant to the distribu-
tion of management strategies. Re-calculation using 
lower risks of transfusion and death (the two-country 
average rather than Zambia’s own rate) did not change 
the cost-saving result. Finally, the threshold analysis 
was more favourable. AMTSL would result in cost-
savings with a probability of postpartum haemorrhage 
AMTSL cost-savings 545among AMTSL cases as high as 8.7% (less than 40% 
of the base case effect) rather than 5% used in our analy-
sis. 
  To summarize, the effectiveness of AMTSL needs 
to be at least 40% of the base case in Zambia, and this is 
well under the estimate of 80% of cause-specific (uter-
ine atony) postpartum haemorrhage. In Guatemala, the 
effect needs to be 80% of the base case for AMTSL to 
be economically favourable, and this is the same as the 
estimate of 80% cause-specific postpartum haemor-
rhage.











                                                                        No. of cases
No PPH 95,000 90,000 95,000 90,000
UT, no transfusion, survival 941 1,883 3,605 7,209
UT, no transfusion, death 97 194 74 147
UT, transfusion, survival 815 1,631 381 762
UT, transfusion, death 84 168 8 16
UT/MRP, no transfusion, survival 526 1,053 517 1,034
UT/MRP, no transfusion, death 54 108 11 21
UT/MRP, transfusion, survival 456 912 55 109
UT/MRP, transfusion, death 47 94 1 2
UT/MRP/BMC, no transfusion, survival 617 1,235 310 620
UT/MRP/BMC, no transfusion, death 64 127 6 13
UT/MRP/BMC, transfusion, survival 535 1,070 33 66
UT/MRP/BMC, transfusion, death 55 110 1 1
UT/BMC, no transfusion, survival 344 688 0 0
UT/BMC, no transfusion, death 35 71 0 0
UT/BMC, transfusion, survival 298 596 0 0
UT/BMC, transfusion, death 31 61 0 0
                                                                     Unit cost (US$)
AMTSL   0.52*   0.56*
   UT 3.89 3.86
   MRP 6.57 8.75
   BMC 0.24 0.22
   Transfusion 69.54  97.12
                                                                   Cost for all cases (US$)
Cost: third stage of labour
   (without complications)  147,270   95,718 82,755 26,843
Cost: management of complications  196,767  393,535 73,953 147,906
Total cost 344,073 489,253 156,708 174,749
Maternal deaths (number) 467 933 100 200
Net cost  -145,216 -18,041
Deaths averted (number) 467 100
*Added personnel costs
AMTSL=Active management of the third stage of labour; BMC=Bimanual compression;
MRP=Manual removal of the placenta; PPH=Postpartum haemorrhage; UT=Uterotonic 
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The recommendation of the International Confedera-
tion of Midwives and the International Federation of 
Gynecology and Obstetrics (ICM/FIGO) for AMTSL 
to prevent postpartum haemorrhage is supported by 
an economic analysis from the facility perspective in a 
Latin American and sub-Saharan African nation. The 
results are quite robust. Logic suggests that the general-
ly-recommended societal perspective would provide an 
even stronger economic argument. Given that the 
deaths prevented are among relatively young women, 
the number of life-years saved or disability-adjusted 
life years averted would be substantial. Maternal death 
may also affect both quality and years of life experi-
enced by children. 
  This analysis was based on the best information 
available consistent with the realities of the context of 
the countries in which we worked. When we made as-
sumptions and analytical decisions we chose to err on 
the side of less cost-savings. For example, we excluded 
rarely-used surgery from our analysis, although inclu-
sion would increase the cost-savings from avoiding 
surgical management of postpartum haemorrhage. We 
also used a relatively low estimate of the incidence of 
postpartum haemorrhage with EMTSL, although one 
study demonstrated a rate as high as 17.9% (7). Greater 
precision of the incidence estimate of postpartum haem-
orrhage would increase the precision of the cost-saving 
results. Nevertheless, the threshold analyses demon-
strated that less than a five-percentage point decrease 
in incidence of PPH with routine practice of AMTSL is 
necessary to obtain positive net benefits. This finding 
suggests that policy need not wait for more precise or 
more valid measures of loss of blood and postpar-
tum haemorrhage.
  Similarly, while more precise and valid estimates 
of the probability of different management strategies 
of postpartum haemorrhage would also be useful, 
the sensitivity analyses demonstrate that policy need 
not wait for these results either. Finally, unless there is 
a substantial decrease in the probability of transfusion, 
the expected costs saved from avoided postpartum 
haemorrhage will continue to be larger than the costs 
of providing AMTSL to a population.
  Training costs were not included in the computa-
tions. The techniques of AMTSL are not necessarily 
new skills for practitioners. AMSTL requires only that 
clinical practitioners amend the timing of common 
clinical practices, or introduce slight variations into 
their manner of practice (e.g. controlled cord traction). 
It was the case in the two countries in which we worked, 
that AMSTL was being introduced into pre-service edu-
cation, and in-service education programming was, in 
large part, being conducted by NGOs. In the case where 
either or both of these assumptions is/are not valid, and 
when in-service education would need to be considered 
as a cost to the facility, these costs would need to be 
included in the cost-benefit calculation. However, here 
training expenses are not anticipated to be a major bur-
den of cost for facility. 
  Costs relating to the theoretical complications of 
AMTSL were also not considered. Improper perform-
ance of the clinical techniques that comprise the prac-
tice of AMTSL can result in the need to implement 
one or more of the strategies for the management of 
postpartum haemorrhage. The meta-analyses conduct-
ed by Prendiville and Elbourne (10) acknowledge that 
there is insufficient information about the incidence of 
complications and side-effects of AMTSL, and no sub-
sequent studies have been reported that enlighten the 
discussion. Our analysis proceeded on the assumption 
that the probabilities of these events are reflected in the 
estimates used in our computations which were based 
on both reported literature and expert opinion.
  The imprecision inherent in the methods that were 
necessary to generate estimates of the probabilities 
of clinical events (including various management 
strategies of postpartum haemorrhage) is the primary 
limitation to this study. However, various approaches 
were used for generating these estimates, and sensiti-
vity analyses were used for exploring the robustness of 
study results against the values of parameters and as-
sumptions. A second limitation is the fact that the study 
sites were primarily in-hospital facilities. Larger facili-
ties may experience the advantage of certain economies 
of scale relating to education of provider, materials, and 
supplies necessary for the implementation of AMTSL. 
These costs may be higher in other healthcare settings 
that have greater challenges to access and supply.
  Recent work shows significant within-country and 
international variation in the use of AMTSL despite the 
apparent economic incentives for adopting it (30,31). 
This study adds to the evidence base that can be used 
for supporting the implementation of AMTSL globally. 
The study is particularly informative because the study 
methods were designed to reflect the specific realities 
and cultural context of the two countries. Evidence 
alone will not, however, necessarily lead to change 
(40). The adoption of AMTSL can be facilitated by 
emerging technology and interest of provider (41,42). 
Emerging technologies that can be used by first-line 
personnel in low-resource settings (43) include single-
dose, pre-filled, oxytocin injection devices (44) and 
AMTSL cost-savings 547rectal administration of misoprostol (which is stable at 
room temperature) as an alternative uterotonic agent 
(45).
  Finally, a recent study in Zambia included in-
terviews with 140 health professionals and administra-
tors (46). The authors, based on the strong enthu-
siasm expressed for the principles of quality assurance 
in that study, recommended that such programmes 
include broad communication of, and uniform adher-
ence to, common standards of clinical practice, includ-
ing AMTSL. Other studies support the cost-effective-
ness of training providers to implement new practices 
(47,48).
  The findings of the present study indicate that the 
proven clinical benefit of AMTSL is also associated 
with a distinct financial benefit to health facilities. We 
believe that these findings, although drawn from very 
cautious cost estimations, assumptions, and proce-
dures, offer a compelling argument in support of the 
introduction of AMTSL as a clinical practice guideline, 
with both client and facility benefits as an outcome.
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c
t
i
v
e
 
m
a
n
a
g
e
m
e
n
t
 
o
f
 
t
h
e
 
t
h
i
r
d
 
s
t
a
g
e
 
o
f
 
l
a
b
o
u
r
;
 
B
M
C
=
B
i
m
a
n
u
a
l
 
c
o
m
p
r
e
s
s
i
o
n
;
 
M
R
P
=
M
a
n
u
a
l
 
r
e
m
o
v
a
l
 
o
f
 
t
h
e
 
p
l
a
c
e
n
t
a
;
 
P
P
H
=
P
o
s
t
p
a
r
t
u
m
 
h
a
e
m
o
r
r
h
a
g
e
;
 
U
T
=
U
t
e
r
o
t
o
n
i
c
AMTSL cost-savings 551